RQM+ Launches SMART Solutions for MedTech Development

Why It Matters

By consolidating fragmented vendor engagements into a single, end‑to‑end framework, SMART Solutions helps MedTech firms navigate tightening MDR/IVDR rules and the surge of software‑driven devices, delivering faster, more predictable product launches.

Key Takeaways

• Integrated framework unifies regulatory, clinical, lab, reimbursement
• Two options: integrated for SMEs, functional for large firms
• Supports complex devices, software, implantables, IVD diagnostics
• Leverages Jordi Labs' extractables/leachables testing expertise
• Aims to cut development risk and accelerate market entry

Pulse Analysis

Regulatory landscapes for medical devices have become increasingly intricate, with the European MDR and IVDR imposing stricter pre‑market evidence requirements and post‑market surveillance obligations. Simultaneously, the rise of AI‑enabled diagnostics and software as a medical device (SaMD) adds layers of compliance, data governance, and cybersecurity scrutiny. Companies that continue to manage these domains through separate consultants often face misaligned timelines, duplicated effort, and hidden compliance gaps, which can delay product launches and inflate costs.

SMART Solutions addresses these challenges by delivering a unified operating model that aligns regulatory strategy, clinical trial design, quality management, reimbursement planning, and laboratory testing under one roof. The integrated option bundles all services for small‑to‑mid‑size firms, while the functional variant lets larger organizations tap specific capabilities without overhauling existing structures. By embedding Jordi Labs’ analytical chemistry expertise—particularly extractables and leachables testing—into the workflow, RQM+ ensures that chemical safety considerations are addressed early, reducing later‑stage redesigns. The AI‑driven data platforms further streamline risk assessments, enabling faster decision‑making across the product’s life cycle.

For the MedTech sector, this holistic approach could reshape partnership dynamics. Firms that adopt SMART Solutions may achieve shorter development cycles, lower regulatory penalties, and smoother market entry, especially in high‑growth therapeutic areas like cardiovascular and neurology. The model also positions RQM+ as a differentiated CRO capable of supporting end‑to‑end innovation, potentially attracting a broader client base seeking to mitigate the escalating complexity of modern device development.